Miromatrix Medical (NASDAQ:MIRO – Get Rating) released its earnings results on Monday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.04), reports. Miromatrix Medical had a negative return on equity of 60.36% and a negative net margin of 91,903.22%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.
Miromatrix Medical Price Performance
Shares of NASDAQ MIRO traded down $0.16 during mid-day trading on Thursday, reaching $4.17. The company had a trading volume of 6,950 shares, compared to its average volume of 55,081. The company has a current ratio of 9.09, a quick ratio of 9.09 and a debt-to-equity ratio of 0.08. The stock has a market cap of $87.15 million, a PE ratio of -2.99 and a beta of -0.85. The company has a 50-day moving average price of $4.16 and a two-hundred day moving average price of $3.66. Miromatrix Medical has a 1-year low of $2.02 and a 1-year high of $7.74.
Wall Street Analyst Weigh In
Separately, Piper Sandler raised their price target on Miromatrix Medical from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Monday.
Institutional Trading of Miromatrix Medical
About Miromatrix Medical
Miromatrix Medical Inc, a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells.
- Get a free copy of the StockNews.com research report on Miromatrix Medical (MIRO)
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- NVIDIA’s Rally Picks Up Pace Into Year End
- Nothing Micro About Super Micro Computer’s Price & Earnings Gains
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.